- Home
- SCPH vs BWAY Comparison
SCPH vs BWAY Comparison
Compare SCPH & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- BWAY
- Stock Information
- Founded
- SCPH 2013
- BWAY 2003
- Country
- SCPH United States
- BWAY Israel
- Employees
- SCPH N/A
- BWAY N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- BWAY Medical/Dental Instruments
- Sector
- SCPH Health Care
- BWAY Health Care
- Exchange
- SCPH Nasdaq
- BWAY Nasdaq
- Market Cap
- SCPH 160.6M
- BWAY 177.4M
- IPO Year
- SCPH 2017
- BWAY 2019
- Fundamental
- Price
- SCPH $3.28
- BWAY $10.28
- Analyst Decision
- SCPH Strong Buy
- BWAY Strong Buy
- Analyst Count
- SCPH 2
- BWAY 3
- Target Price
- SCPH $15.00
- BWAY $13.17
- AVG Volume (30 Days)
- SCPH 251.3K
- BWAY 57.5K
- Earning Date
- SCPH 03-12-2025
- BWAY 03-05-2025
- Dividend Yield
- SCPH N/A
- BWAY N/A
- EPS Growth
- SCPH N/A
- BWAY N/A
- EPS
- SCPH N/A
- BWAY 0.04
- Revenue
- SCPH $30,278,000.00
- BWAY $38,631,000.00
- Revenue This Year
- SCPH $173.14
- BWAY $388.82
- Revenue Next Year
- SCPH $131.01
- BWAY $18.70
- P/E Ratio
- SCPH N/A
- BWAY $128.37
- Revenue Growth
- SCPH 303.87
- BWAY 34.19
- 52 Week Low
- SCPH $3.08
- BWAY $4.61
- 52 Week High
- SCPH $6.54
- BWAY $11.25
- Technical
- Relative Strength Index (RSI)
- SCPH 41.79
- BWAY 46.35
- Support Level
- SCPH $3.15
- BWAY $10.24
- Resistance Level
- SCPH $3.52
- BWAY $10.89
- Average True Range (ATR)
- SCPH 0.18
- BWAY 0.47
- MACD
- SCPH -0.00
- BWAY -0.04
- Stochastic Oscillator
- SCPH 15.22
- BWAY 10.34
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.